Papillon-Cavanagh et al. evaluated the impact of STK11 and KEAP1 mutations in NSCLC samples on the response to various treatments, including PD-1/PD-L1 inhibitors, EGFR inhibitors, vascular endothelial growth factor inhibitors, platinum chemotherapy, and chemotherapy alone [73]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.